Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs
{{output}}
Obviousness-type double patenting is allowed only in the US, but only if a terminal disclaimer and the same ownership are made for the expiry of the patent. Historically, this provision has hampered the entry of generic and biosimilar drugs due to the legal co... ...
